DIABETES MONITORING AND CONTROL TECHNOLOGY

VolverGo back

Resultados 72 results. LastUpdate Updated on 05/12/2021 [15:33:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Page1/3 nextPage   results/page


TRANSCUTANEOUS ANALYTE SENSOR

Publication No.: US2021369114A1 02/12/2021

Applicant:

DEXCOM INC [US]

US_2019021596_A1

Absstract of: US2021369114A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

SILICON CARBIDE NANOPARTICLES FIBROUS MEMBRANE FOR IMPLANTABLE GLUCOSE SENSOR INTEGRATED WITH CHRONOAMPEROMETRIC POTENTIOSTAT

Publication No.: US2021369157A1 02/12/2021

Applicant:

UNIV SOUTH FLORIDA [US]

Absstract of: US2021369157A1

The present disclosure presents glucose monitoring systems and methods. One such system comprises a glucose monitoring sensor having at least a counter electrode, a reference electrode, and a working electrode; and a silicon-carbide-silicon-carbide-nanoparticles-electrospun-nanofibrous-membrane contacting the working electrode. The system further includes a glucose oxidase enzyme solution contacting the silicon-carbide-silicon-carbide-nanoparticles-electrospun-nanofibrous-membrane, wherein a conductive polymer membrane assists in binding the glucose oxidase enzyme composition with the silicon-carbide-silicon-carbide-nanoparticles-electrospun-nanofibrous-membrane. Other systems and methods are also provided.

traducir

BURDEN-FREE BLOOD GLUCOSE MANAGEMENT FOR INSULIN-REQUIRING DIABETES WITH MINIMAL USER INTERACTION

Publication No.: US2021375422A1 02/12/2021

Applicant:

NUDGE BG INC [US]

WO_2021146468_A1

Absstract of: US2021375422A1

Some embodiments include burden-free insulin delivery systems and methods. Some embodiments include a method comprising: receiving previous insulin delivery data at a user device from an insulin pump; receiving estimated glucose data at the user device from a continuous glucose monitor; determining that the estimated glucose value is approaching or has passed a threshold; and in response to determining that the estimated glucose value is approaching or has surpassed the threshold, not providing an indication to the user through a user interface that the estimated glucose value is approaching or surpassed the threshold.

traducir

INSULIN DELIVERY ARRANGEMENT AND METHOD FOR INSULIN DOSING

Publication No.: US2021369969A1 02/12/2021

Applicant:

MYSUGR GMBH [AT]

KR_20210129651_PA

Absstract of: US2021369969A1

The disclosure concerns an insulin delivery arrangement including a hand-operable insulin delivery device which includes an adjusting unit for presetting of an insulin dose and an applicator unit that can be triggered to deliver the preset insulin dose to a user. In order to ease burden of insulin dosing, a dose converter is adapted to receive an actual setting for the insulin dose as an input and to provide as an output a carbohydrate value equivalent to an amount of meal carbohydrates which can be compensated by the respective insulin dose. A display is used for displaying the carbohydrate value in parallel to the insulin dose.

traducir

Analyte Sensors and Sensing Methods for Detecting Inhibitors of Diaphorase

Publication No.: US2021369155A1 02/12/2021

Applicant:

ABBOTT DIABETES CARE INC [US]

Absstract of: US2021369155A1

Analyte sensors featuring an enzyme system comprising diaphorase and a NAD-dependent dehydrogenase may be utilized to detect inhibitors of diaphorase, provided that the transfer of electrons to a working electrode is rate-limiting with respect to the diaphorase. Such analyte sensors may comprise a sensor tail comprising at least a first working electrode, a first active area disposed upon a surface of the first working electrode, and an analyte-permeable membrane overcoating at least the first active area. The enzyme system comprises NAD, reduced NAD, or any combination thereof; a NAD-dependent dehydrogenase, such as NAD-dependent glucose dehydrogenase; and diaphorase. Inhibitors of diaphorase that may be detected include, for example, warfarin, dicoumarol, and similar compounds. A second active area may be present to facilitate detection of an analyte differing from the inhibitor of diaphorase.

traducir

GLUCOSE PREDICTION USING MACHINE LEARNING AND TIME SERIES GLUCOSE MEASUREMENTS

Publication No.: US2021369151A1 02/12/2021

Applicant:

DEXCOM INC [US]

US_2021375448_A1

Absstract of: US2021369151A1

Glucose prediction using machine learning (ML) and time series glucose measurements is described. Given the number of people that wear glucose monitoring devices and because some wearable glucose monitoring devices can produce measurements continuously, a platform providing such devices may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process and covers a robust number of state spaces unlikely to be covered without the enormous amount of data. In implementations, a glucose monitoring platform includes an ML model trained using historical time series glucose measurements of a user population. The ML model predicts upcoming glucose measurements for a particular user by receiving a time series of glucose measurements up to a time and determining the upcoming glucose measurements of the particular user for an interval subsequent to the time based on patterns learned from the historical time series glucose measurements.

traducir

ZWITTERION SURFACE MODIFICATIONS FOR CONTINUOUS SENSORS

Publication No.: US2021361205A1 25/11/2021

Applicant:

DEXCOM INC [US]

JP_2021164475_A

Absstract of: US2021361205A1

Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a sensor configured to generate a signal associated with a concentration of an analyte; and a sensing membrane located over the sensor. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.

traducir

BODY ATTACHABLE UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Publication No.: US2021361197A1 25/11/2021

Applicant:

I SENS INC [KR]

AU_2019347534_A1

Absstract of: US2021361197A1

The present disclosure relates to a body-attachable unit for continuously measuring blood glucose. As the body-attachable unit is manufactured to be assembled in an applicator, additional effort is minimized such that the body-attachable unit can be attached to the body by simply operating the applicator. In particular, since the body-attachable unit is provided with a wireless communication chip such that communication with an external terminal is possible, the body-attachable unit can be used simply and conveniently without additional work of connecting a separate transmitter, and thus can be maintained more easily. In addition, since the body-attachable unit is operated by an operation of a user after being attached to the body, the start time of the operation can be adjusted to an appropriate time according to the needs of the user. Accordingly, the body-attachable unit can be operated in a stabilized state, thereby allowing for more accurate blood glucose measurement.

traducir

MANAGEMENT OF INSUFFICIENT HYPOGLYCEMIA RESPONSE

Publication No.: US2021361866A1 25/11/2021

Applicant:

MEDTRONIC MINIMED INC [US]

CN_109891510_A

Absstract of: US2021361866A1

A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of obtaining an insulin-on-board (IOB) value, wherein the IOB value is a quantity of insulin remaining in a patient following delivery of a bolus of insulin, scaling a total daily dose (TDD) value by a factor, to generate a result having a value that is less than the TDD value, based on determining that the IOB value is greater than the result, identifying a condition in which the patient's glucose level will continue to decrease after suspension of basal insulin dosage delivery, and responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.

traducir

INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK

Publication No.: US2021361867A1 25/11/2021

Applicant:

ABBOTT DIABETES CARE INC [US]
CAMBRIDGE ENTPR LTD [GB]

US_2019151540_A1

Absstract of: US2021361867A1

A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.

traducir

TRANSCUTANEOUS ANALYTE SENSOR

Publication No.: US2021361198A1 25/11/2021

Applicant:

DEXCOM INC [US]

US_2021321914_A1

Absstract of: US2021361198A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

GIGAHERTZ FREQUENCY FRINGING NEAR-FIELD BIOMEDICAL SENSOR

Publication No.: US2021361180A1 25/11/2021

Applicant:

CHIEN JUN CHAU [US]
CHEN STANLEY YUANSHIH [US]

Absstract of: US2021361180A1

A near-field sensor method and device for obtaining biomedical information is disclosed. A transmission-line aperture arrangement configured to guide electromagnetic waves and emit near-field fringing energy, is placed near the skin. The transmission line is excited at a narrow-band Gigahertz frequency. The near-field fringing energy emitted by the sensor device penetrates at least partially into the skin and underlying blood vessels, and this energy is partially absorbed and partially phase shifted in a time varying manner according to the changes in tissue physiology. The status of the sensor device is monitored over a plurality of time intervals, and changes in both the phase and the amplitude of the signals passing though the transmission line are used to determine biomedical information such as heart rates, PTT, blood pressure, and glucose levels. Various transmission-line configurations, and various reference transmission-line methods to reduce low-frequency noise, are also discussed.

traducir

SYSTEMS, DEVICES, AND METHODS FOR ANALYTE MONITORING AND BENEFITS THEREOF

Publication No.: US2021366609A1 25/11/2021

Applicant:

ABBOTT DIABETES CARE INC [US]

Absstract of: US2021366609A1

A method of treatment of a type 2 diabetic patient includes selecting a type 2 diabetic patient having a predetermined comorbidity for treatment, initiating a continuous glucose monitor regimen for the selected type 2 diabetic patient, wherein after six months of initiation of the continuous glucose monitor regimen, a rate of hospitalization for a predetermined diagnostic category of the selected patient having the predetermined comorbidity is reduced by at least 12% relative to an average rate of hospitalization for the predetermined diagnostic category of selected patients having the predetermined comorbidity without the continuous glucose monitor regimen.

traducir

HOSPITAL MANAGEMENT SYSTEM AND THE CONTROL METHOD THEREOF

Publication No.: US2021366260A1 25/11/2021

Applicant:

INFOMINING CO LTD [KR]

KR_102251599_B1

Absstract of: US2021366260A1

Disclosed is a hospital management system including a communication unit for transmitting and receiving data, a memory for storing at least one instruction, and at least one processor for executing the at least one instruction stored in the memory. The at least one processor controls the communication unit to receive biometrics of a patient in real time, determines a disease symptom variation of the patient based on an examination result and the biometrics, wherein the examination result includes at least one of CT, Xray, MRI results, a body temperature, a pulse, a blood pressure, an oxygen saturation, an electrocardiogram, or a blood sugar level of the patient, controls the communication unit to transmit at least one of the examination result, the biometrics, or the disease symptom variation to a hospital electronic medical record system and a medical staff device, and receives prescription information from a medical staff, and performs prescription corresponding to the prescription information for the patient.

traducir

CONFIGURABLE TARGET GLUCOSE VALUES

Publication No.: US2021361864A1 25/11/2021

Applicant:

MEDTRONIC MINIMED INC [US]

CA_3110084_PA

Absstract of: US2021361864A1

A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of obtaining a first target value for a glucose level of a patient, modifying a glucose setpoint from a second target value to the first target value, and regulating the glucose level of the patient to the modified glucose setpoint based on controlling insulin delivery by an insulin infusion device.

traducir

METHODS OF WIRELESS COMMUNICATION IN AN INFUSION PUMP SYSTEM

Publication No.: US2021368442A1 25/11/2021

Applicant:

TANDEM DIABETES CARE INC [US]

US_2020329433_A1

Absstract of: US2021368442A1

Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, a smartphone or other multi-purpose consumer electronic device and/or a dedicated remote controller for the infusion pump. Communications among these devices can be coordinated to increase efficiency and conserve battery power.

traducir

SYSTEMS, DEVICES, AND METHODS OF ANALYTE MONITORING

Publication No.: US2021361199A1 25/11/2021

Applicant:

ABBOTT DIABETES CARE INC [US]

Absstract of: US2021361199A1

A glucose monitoring system includes a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level, and a reader device comprising a wireless communication circuitry configured to receive the data indicative of the analyte level, and one or more processors coupled with a memory. The memory is configured to store instructions that, when executed by the one or more processors, cause the one or more processors to: determine a frequency of interaction over a first time period based on one or more instances of user operation of the reader device, and output a first notification if the determined frequency of interaction is below a predetermined target level of interaction and output a second notification if the determined frequency of interaction is above the predetermined target level of interaction, wherein below the predetermined target level of interaction, an increase in the determined frequency of interaction corresponds to a first improvement in a metabolic parameter, and above the predetermined target level of interaction, an increase in the determined frequency of interaction corresponds to a second improvement in the metabolic parameter.

traducir

ENZYME IMMOBILIZED ADHESIVE LAYER FOR ANALYTE SENSORS

Publication No.: US2021356420A1 18/11/2021

Applicant:

DEXCOM INC [US]

AU_2021257924_A1

Absstract of: US2021356420A1

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises an enzyme layer, wherein the enzyme layer comprises an enzyme and a polymer comprising polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The enzyme layer protects the enzyme and prevents it from leaching from the sensing membrane into a host or deactivating.

traducir

METHOD AND SYSTEM FOR NON-INVASIVE OPTICAL BLOOD GLUCOSE DETECTION UTILIZING SPECTRAL DATA ANALYSIS

Publication No.: US2021353186A1 18/11/2021

Applicant:

ST LOUIS MEDICAL DEVICES INC [US]

US_2021228117_A1

Absstract of: US2021353186A1

Systems and methods are disclosed for non-invasively measuring blood glucose levels in a biological sample based on spectral data. This includes utilizing at least one light source configured to strike a target area of a sample, utilizing at least one light filter positioned to receive light transmitted through the target area from the at least one light source, utilizing at least one light detector positioned to receive light from the at least one light source and filtered by the at least one light filter, and to generate an output signal, having a time dependent current, which is indicative of the power of light detected, receiving the output signal from the at least one light detector with a processor and based on the received output signal, calculating the attenuance attributable to blood in a sample with a signal-to-noise ratio of at least 20-to-1; and determining a blood glucose level.

traducir

LOW OXYGEN IN VIVO ANALYTE SENSOR

Publication No.: US2021353187A1 18/11/2021

Applicant:

DEXCOM INC [US]

US_2019183396_A1

Absstract of: US2021353187A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous and subcutaneous measurement of glucose in a host.

traducir

TUNABLE HYBRID III-V/ IV LASER SENSOR SYSTEM-ON-A-CHIP FOR REAL-TIME MONITORING OF A BLOOD CONSTITUENT CONCENTRATION LEVEL

Publication No.: US2021353183A1 18/11/2021

Applicant:

BROLIS SENSOR TECH UAB [LT]
UNIV GENT [BE]
IMEC VZW [BE]

JP_2020520768_A

Absstract of: US2021353183A1

A spectroscopic laser sensor based on hybrid III-V/IV system-on-a-chip technology. The laser sensor is configured to either (i) be used with a fiber-optic probe connected to an intravenous/intra-arterial optical catheter for direct invasive blood analyte concentration level measurement or (ii) be used to measure blood analyte concentration level non-invasively through an optical interface attached, e.g., to the skin or fingernail bed of a human. The sensor includes a III-V gain-chip, e.g., an AlGaInAsSb/GaSb based gain-chip and a photonic integrated circuit, with laser wavelength filtering, laser wavelength tuning, laser wavelength monitoring, laser signal monitoring and signal output sections realized on a chip by combining IV-based semiconductor substrates and flip-chip AlGaInAsSb/GaSb based photodetectors and embedded electronics for signal processing. Embodiments of the invention may be applied for real-time monitoring of critical blood analyte concentration levels such as lactates, urea, glucose, ammonia, albumin, etc.

traducir

SYSTEMS AND METHODS FOR AUTOMATED INSULIN DELIVERY RESPONSE TO MEAL ANNOUNCEMENTS

Publication No.: US2021353857A1 18/11/2021

Applicant:

TANDEM DIABETES CARE INC [US]

Absstract of: US2021353857A1

Disclosed herein are apparatuses and methods that account for meal announcements in closed loop insulin delivery systems. Rather than simply increasing an insulin delivery rate in response to the meal announcement, the closed loop algorithm can be modified to increase the insulin on board tolerance during eating periods. This approach utilizes the stability of the cascaded loop in the closed loop algorithm to prevent the oscillations in glucose levels that can occur by simply increasing the basal rate.

traducir

SYSTEM AND METHOD FOR DUAL MODEL-BASED EARLY PREDICTION OF HEART DISEASE FOR INDIAN TYPE-2 DIABETES MELLITUS PATIENTS

Publication No.: AU2021105334A4 18/11/2021

Applicant:

AHMAD JAMAL [IN]
AHMED AQUIL [IN]
KHAN YUSUFI FAIZ NOOR [IN]

Absstract of: AU2021105334A4

The present invention generally relates to a system and method for dual model-based early prediction of heart disease for Indian type-2 diabetes mellitus patients. The first model is a full model which tested all of the collected variables, whereas the second model is a partial model and it consisted of selected variables. The patients are included in the system sample if they experienced angiography, left ventricular hypertrophy, left anterior hemiblock, myocardial infarction, right bundle branch block, left bundle branch block, left ventricular diastolic dysfunction, angina, coronary artery bypass grafting and ischemic cardiomyopathy within the follow up time period of 5 years. N co CN CD Ea- --Ii >L

traducir

Membrane layers for analyte sensors

Publication No.: AU2021257924A1 18/11/2021

Applicant:

DEXCOM INC [US]

Absstract of: AU2021257924A1

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises a biointerface layer which interfaces with a biological fluid containing the analyte to be measured. The biointerface layer can comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The sensing membrane can also comprise an enzyme layer, wherein the enzyme layer comprises an enzyme and a polymer comprising polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The sensing membrane can also comprise a diffusion-resistance layer, which can comprise a base polymer having a lowest Tg of greater than -50C.

traducir

ISLET-LIKE CELL CLUSTER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Nº publicación: WO2021228104A1 18/11/2021

Applicant:

CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE CHINESE ACAD OF SCIENCES [CN]

CN_113637630_A

Absstract of: WO2021228104A1

Provided is an artificially cultured islet-like cell cluster, characterized in that: the cell cluster is obtained by stem cell differentiation. The cell cluster without enrichment comprises: (a) 20%-90% of islet β-cells; and (b) 5%-70% of islet α-cells. Human pluripotent stem cells are cultured to obtain a culture system of the islet-like cell cluster. Also provided are a model for constructing an islet microenvironment using the islet-like cell cluster, an artificial pancreas device prepared using the islet-like cell cluster, and a pharmaceutical composition containing the islet-like cell cluster. The artificially cultured islet-like cell cluster provided in the present invention can effectively release insulin under the stimulation of secretagogues such as glucose, and is used in an in vivo model of type I diabetes, so that the blood sugar level of a mouse having type I diabetes can remain within the normal range for a long time.

traducir

Page1/3 nextPage results/page

punteroimgGo back